Oral toxicities secondary to TROP2 and HER2-directed antibody drug conjugates: a multicenter retrospective cohort study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag359 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Paolo J Fantozzi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, 00187, Italy. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Cell Adhesion Molecules, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
The aim of this multicenter retrospective cohort study was to characterize the incidence, clinical presentation, timing, severity, and management of oral toxicities (OTs) associated with TROP2-directed (datopotamab deruxtecan and sacituzumab govitecan) and HER2-directed (trastuzumab deruxtecan) antibody-drug conjugates in patients with advanced-stage cancers.
Methods
A retrospective medical-records review of 207 patients was conducted to characterize antibody–drug conjugate (ADC)-associated OTs. Patients had been treated for advanced-stage cancers treated with TROP2 (sacituzumab govitecan and datopotamab deruxtecan) and HER2-directed ADCs (trastuzumab deruxtecan) at the Sapienza University–Hospital and Miami Cancer Institute between 2024 and 2025. Multivariate logistic regressions were performed to evaluate any correlation between the ADC type and prevalence, type, severity, time of onset, and time to resolution of OTs.
Results
Overall, 47 patients (22.7%) developed OTs, with a median onset time of 7.5 days (range: 1-358). The OT prevalence was similar between TROP2 (n = 27, 23.5%) and HER2-directed (n = 20, 21.7%) ADCs, however, oral mucositis (OM) was more frequent with TROP2-directed ADCs (14.8% vs 5.4%, P = .04), whereas xerostomia (10.9% vs 6.1%, P = .31) and dysgeusia (9.8% vs 5.2%, P = .28) were more common and more severe with HER2-directed ADCs, although not reaching statistical significance. Patients receiving TROP2-directed ADCs had a 3.02-fold higher-risk of developing OM compared to those receiving HER2-directed ADCs (95% CI: 1.07-8.52, P = .040). In cases of OM, the trajectory of TROP2-associated OM was more acute than with HER-2-associated OM with earlier onset (P = .035) and quicker resolution (P = .045). Management of OTs was provided for 29 (14.0%) patients with the majority of them receiving TROP2-directed ADCs (n = 21, 17.3%). With regard to OTs, patients developing OM were associated with a greater need for management (n = 19/22; P = .001), compared to xerostomia (n = 8/17; P = .471) and dysgeusia (n = 2/15; P = .196). Ultimately, ADC dose reduction (DR) was required in 43 patients (20.8%) and was significantly more frequent with TROP2-directed ADCs (26.1% vs 14.1%, P = .039).
Conclusion
TROP2-directed ADCs are associated with a higher-risk of OM (P = .040) with earlier onset of toxicities (P = .035), and greater DR requirements (P = .039). In contrast, HER2-directed ADCs are associated with more prevalent xerostomia and dysgeusia, a higher overall severity, and later onset but potentially longer duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, 00187, Italy.
- Department of Head and Neck, Umberto I/Sapienza University Hospital, Rome, 00187, Italy.
- Divisions of Oral Medicine and Dentistry, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston, MA 02115, United States.
- Biomodels, LLC and Primary Endpoint Solutions, LLC, Waltham, MA 02451, United States.
- Department of Radiological, Pathological and Oncological Sciences, Umberto I/Sapienza University Hospital, Rome, 00187, Italy.
- Medical Oncology Unit, Umberto I/Sapienza University Hospital, Rome, 00187, Italy.
ORCID-Profile: Paolo J Fantozzi, Andrea Botticelli, Simone Scagnoli, Monica Verrico, Maria Vittoria Bonomo, Lucia Borghetti
Zitieren
APA
Fantozzi, P. J., Sonis, S., Botticelli, A., Scagnoli, S., Verrico, M., Bianchini, G., Bonomo, M. V., Bonadonna, C., Casagrande, M., Borghetti, L., Tenore, G., Das, S., Diaz, J. P., Romeo, U., & Villa, A. (2026). Oral toxicities secondary to TROP2 and HER2-directed antibody drug conjugates: a multicenter retrospective cohort study. The Oncologist. https://doi.org/10.1093/oncolo/oyag359
Vancouver
Fantozzi PJ, Sonis S, Botticelli A, Scagnoli S, Verrico M, Bianchini G, et al. Oral toxicities secondary to TROP2 and HER2-directed antibody drug conjugates: a multicenter retrospective cohort study. The Oncologist. 2026. doi:10.1093/oncolo/oyag359
BibTeX
@article{Fantozzi2026,
author = {Fantozzi, Paolo J and Sonis, Stephen and Botticelli, Andrea and Scagnoli, Simone and Verrico, Monica and Bianchini, Giulia and Bonomo, Maria Vittoria and Bonadonna, Chiara and Casagrande, Mathilde and Borghetti, Lucia and Tenore, Gianluca and Das, Sankalp and Diaz, John P and Romeo, Umberto and Villa, Alessandro},
title = {Oral toxicities secondary to TROP2 and HER2-directed antibody drug conjugates: a multicenter retrospective cohort study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag359}
}
EUVIMED